3. Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015;46:976–987.
6. Corte TJ, Copley SJ, Desai SR, et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012;39:661–668.
8. Ahmad K, Barba T, Gamondes D, et al. Interstitial pneumonia with autoimmune features: clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respir Med 2017;123:56–62.
10. Sambataro G, Sambataro D, Torrisi SE, et al. Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients. Respir Med 2019;150:154–160.
12. Kim HC, Lee JH, Chae EJ, Song JS, Song JW. Long-term clinical course and outcome of interstitial pneumonia with autoimmune features. Respirology 2020;25:636–643.
13. Chartrand S, Lee JS, Swigris JJ, Stanchev L, Fischer A. Clinical characteristics and natural history of autoimmune forms of interstitial lung disease: a single-center experience. Lung 2019;197:709–713.
14. Dai J, Wang L, Yan X, et al. Clinical features, risk factors, and outcomes of patients with interstitial pneumonia with autoimmune features: a population-based study. Clin Rheumatol 2018;37:2125–2132.
15. Chartrand S, Swigris JJ, Stanchev L, Lee JS, Brown KK, Fischer A. Clinical features and natural history of interstitial pneumonia with autoimmune features: a single center experience. Respir Med 2016;119:150–154.
16. Sebastiani M, Cassone G, De Pasquale L, et al. Interstitial pneumonia with autoimmune features: a single center prospective follow-up study. Autoimmun Rev 2020;19:102451.
17. Yoshimura K, Kono M, Enomoto Y, et al. Distinctive characteristics and prognostic significance of interstitial pneumonia with autoimmune features in patients with chronic fibrosing interstitial pneumonia. Respir Med 2018;137:167–175.
19. Tian M, Huang W, Ren F, et al. Comparative analysis of connective tissue disease-associated interstitial lung disease and interstitial pneumonia with autoimmune features. Clin Rheumatol 2020;39:575–583.
21. Alevizos MK, Giles JT, Patel NM, Bernstein EJ. Risk of progression of interstitial pneumonia with autoimmune features to a systemic autoimmune rheumatic disease. Rheumatology (Oxford) 2020;59:1233–1240.
22. Schurawitzki H, Stiglbauer R, Graninger W, et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 1990;176:755–759.
23. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655–2666.
24. Sanchez-Cano D, Ortego-Centeno N, Callejas JL, et al. Interstitial lung disease in systemic sclerosis: data from the Spanish scleroderma study group. Rheumatol Int 2018;38:363–374.
26. Chen IJ, Jan Wu YJ, Lin CW, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009;28:639–646.
27. Hayashi S, Tanaka M, Kobayashi H, et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol 2008;35:260–269.
29. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008;168:159–166.
31. Roca F, Dominique S, Schmidt J, et al. Interstitial lung disease in primary Sjögren’s syndrome. Autoimmun Rev 2017;16:48–54.
32. Dong X, Zhou J, Guo X, et al. A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren’s syndrome-related interstitial lung disease in a Chinese population. Clin Rheumatol 2018;37:2981–2988.
35. Koenig M, Dieude M, Senecal JL. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008;7:588–593.
36. Spagnolo P, Cottin V. Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine. J Med Genet 2017;54:93–99.
37. McLean-Tooke A, Moore I, Lake F. Idiopathic and immune-related pulmonary fibrosis: diagnostic and therapeutic challenges. Clin Transl Immunology 2019;8:e1086.
39. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006;65:366–371.
40. Lee HS, Irigoyen P, Kern M, et al. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum 2007;56:1745–1753.
42. Karabulut G, Kitapcioglu G, Inal V, et al. Cigarette smoking in primary Sjögren’s syndrome: positive association only with ANA positivity. Mod Rheumatol 2011;21:602–607.
44. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–2581.
46. Sulli A, Secchi ME, Pizzorni C, Cutolo M. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 2008;67:885–887.
48. Aringer M, Costenbader K, Daikh D, et al. 2019 European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1400–1412.
49. Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015;372:1734–1747.
52. Gao Y, Moua T. Treatment of the connective tissue disease-related interstitial lung diseases: a narrative review. Mayo Clin Proc 2020;95:554–573.
53. Li Y, Zheng Z, Han Q, et al. IPAF should receive early treatment for sharing similar clinical characteristics as CTD-ILD: a report from 273 Chinese patients. Clin Rheumatol 2020;39:3817–3823.
54. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760–1769.
55. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083–2092.
57. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071–2082.
59. Acharya N, Sharma SK, Mishra D, Dhooria S, Dhir V, Jain S. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial. Rheumatol Int 2020;40:703–710.
60. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019;380:2518–2528.
63. Sambataro G, Vancheri A, Torrisi SE, et al. The morphological domain does not affect the rate of progression to defined autoimmune diseases in patients with interstitial pneumonia with autoimmune features. Chest 2020;157:238–242.
65. Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers 2018;4:18001.
66. Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 2017;76:1700–1706.
67. Peelen L, Wells AU, Prijs M, et al. Fibrotic idiopathic interstitial pneumonias: mortality is linked to a decline in gas transfer. Respirology 2010;15:1233–1243.
68. Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011;37:356–363.
70. Kelly BT, Moua T. Overlap of interstitial pneumonia with autoimmune features with undifferentiated connective tissue disease and contribution of UIP to mortality. Respirology 2018;23:600–605.